Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94%…
News
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024…
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024…
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Akari Therapeutics to Present at Emerging Growth Conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a…
Akari Therapeutics to Present at Emerging Growth Conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a…
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide, a PTHR1 Agonist in Phase 3 for the Treatment of Hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide, a PTHR1 Agonist in Phase 3 for the Treatment of Hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…